MyFinsight
Home
Blog
About
Marketable securities
$57,366K
(38.69%↑ Y/Y)
Cash and cash
equivalents
$36,537K
(-33.16%↓ Y/Y)
Accounts receivable
$34,060K
(31.46%↑ Y/Y)
Inventory
$13,324K
(55.09%↑ Y/Y)
Prepaid expenses,
current
$3,586K
(-7.79%↓ Y/Y)
Other assets, current
$199K
(172.60%↑ Y/Y)
Total current assets
$145,072K
(6.22%↑ Y/Y)
Intangible assets, net
$36,522K
(-21.05%↓ Y/Y)
Lease right-of-use
assets, net
$4,420K
(56.29%↑ Y/Y)
Deferred tax assets
$3,830K
(-45.87%↓ Y/Y)
Prepaid expenses and
other, long-term
$2,789K
(56.25%↑ Y/Y)
Property and equipment,
net
$103K
(-73.45%↓ Y/Y)
Total assets
$192,736K
(-1.12%↓ Y/Y)
Total liabilities and
stockholders equity
$192,736K
(-1.12%↓ Y/Y)
Total stockholders
equity
$138,544K
(32.30%↑ Y/Y)
Total liabilities
$54,192K
(-39.92%↓ Y/Y)
Accumulated deficit
-$1,279,339K
(2.05%↑ Y/Y)
Accumulated other
comprehensive (loss) income
-$45K
(-221.43%↓ Y/Y)
Additional paid-in capital
$1,417,923K
(0.51%↑ Y/Y)
Total current
liabilities
$49,825K
(-37.01%↓ Y/Y)
Lease liabilities,
long-term
$4,367K
Common stock - 0.0001
par value per share...
$5K
(0.00%↑ Y/Y)
Accrued expenses
$45,130K
(41.93%↑ Y/Y)
Accounts payable
$3,105K
(-42.75%↓ Y/Y)
Post-marketing commitment
liability
$1,140K
(-65.39%↓ Y/Y)
Lease liabilities,
current
$450K
(-89.69%↓ Y/Y)
Back
Back
Balance Sheet
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)
source: myfinsight.com